Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents

Alan P. Kozikowski, Jiazhong Zhang, Fajun Nan, Pavel A. Petukhov, Ewa Grajkowska, Jarda T. Wroblewski, Tatsuo Yamamoto, Tomasz Bzdega, Barbara Wroblewska, Joseph H. Neale

Research output: Contribution to journalArticle

Abstract

The neuropeptidase glutamate carboxypeptidase II (GCPII) hydrolyzes N-acetyl-L-aspartyl-L-glutamate (NAAG) to liberate N-acetylaspartate and glutamate. GCPII was originally cloned as PSMA, an Mr 100 000 type II transmembrane glycoprotein highly expressed in prostate tissues. PSMA/GCPII is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. Inhibition of brain GCPII may have therapeutic potential in the treatment of certain disease states arising from pathologically overactivated glutamate receptors. Recently, we reported that certain urea-based structures act as potent inhibitors of GCPII (J. Med. Chem. 2001, 44, 298). However, many of the potent GCPII inhibitors prepared to date are highly polar compounds and therefore do not readily penetrate the blood-brain barrier. Herein, we elaborate on the synthesis of a series of potent, urea-based GCPII inhibitors from the lead compound 3 and provide assay data for these ligands against human GCPII. Moreover, we provide data revealing the ability of one of these compounds, namely, 8d, to reduce the perception of inflammatory pain. Within the present series, the γ-tetrazole bearing glutamate isostere 7d is the most potent inhibitor with a Ki of 0.9 nM. The biological evaluation of these compounds revealed that the active site of GCPII likely comprises two regions, namely, the pharmacophore subpocket and the nonpharmacophore subpocket. The pharmacophore subpocket is very sensitive to structural changes, and thus, it appears important to keep one of the glutamic acid moieties intact to maintain the potency of the GCPII inhibitors. The site encompassing the nonpharmacophore subpocket that binds to glutamate's α-carboxyl group is sensitive to structural change, as shown by compounds 6b and 7b. However, the other region of the nonpharmacophore subpocket can accommodate both hydrophobic and hydrophilic groups. Thus, an aromatic ring can be introduced to the inhibitor, as in 8b and 8d, thereby increasing its hydrophobicity and thus potentially its ability to cross the blood-brain barrier. Intrathecally administered 8d significantly reduced pain perception in the formalin model of rat sensory nerve injury. A maximal dose of morphine (10 mg) applied in the same experimental paradigm provided no significant increase in analgesia in comparison to 8d during phase 1 of this pain study and modestly greater analgesia than 8d in phase 2. These urea-based inhibitors of GCPII thus offer a novel approach to pain management.

Original languageEnglish (US)
Pages (from-to)1729-1738
Number of pages10
JournalJournal of Medicinal Chemistry
Volume47
Issue number7
DOIs
StatePublished - Mar 25 2004
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Analgesics
Urea
Catalytic Domain
Glutamic Acid
Pain Perception
Aptitude
Blood-Brain Barrier
Analgesia
Bearings (structural)
Lead compounds
Chromosomes, Human, Pair 11
Glutamate Receptors
Hydrolases
Pain Management
Hydrophobicity
Chromosomes
Hydrophobic and Hydrophilic Interactions
Folic Acid
Morphine

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Kozikowski, A. P., Zhang, J., Nan, F., Petukhov, P. A., Grajkowska, E., Wroblewski, J. T., ... Neale, J. H. (2004). Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents. Journal of Medicinal Chemistry, 47(7), 1729-1738. https://doi.org/10.1021/jm0306226

Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II : Efficacy as Analgesic Agents. / Kozikowski, Alan P.; Zhang, Jiazhong; Nan, Fajun; Petukhov, Pavel A.; Grajkowska, Ewa; Wroblewski, Jarda T.; Yamamoto, Tatsuo; Bzdega, Tomasz; Wroblewska, Barbara; Neale, Joseph H.

In: Journal of Medicinal Chemistry, Vol. 47, No. 7, 25.03.2004, p. 1729-1738.

Research output: Contribution to journalArticle

Kozikowski, AP, Zhang, J, Nan, F, Petukhov, PA, Grajkowska, E, Wroblewski, JT, Yamamoto, T, Bzdega, T, Wroblewska, B & Neale, JH 2004, 'Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents', Journal of Medicinal Chemistry, vol. 47, no. 7, pp. 1729-1738. https://doi.org/10.1021/jm0306226
Kozikowski, Alan P. ; Zhang, Jiazhong ; Nan, Fajun ; Petukhov, Pavel A. ; Grajkowska, Ewa ; Wroblewski, Jarda T. ; Yamamoto, Tatsuo ; Bzdega, Tomasz ; Wroblewska, Barbara ; Neale, Joseph H. / Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II : Efficacy as Analgesic Agents. In: Journal of Medicinal Chemistry. 2004 ; Vol. 47, No. 7. pp. 1729-1738.
@article{31c02c432f5644ec95acc4fce37cdd5d,
title = "Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents",
abstract = "The neuropeptidase glutamate carboxypeptidase II (GCPII) hydrolyzes N-acetyl-L-aspartyl-L-glutamate (NAAG) to liberate N-acetylaspartate and glutamate. GCPII was originally cloned as PSMA, an Mr 100 000 type II transmembrane glycoprotein highly expressed in prostate tissues. PSMA/GCPII is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. Inhibition of brain GCPII may have therapeutic potential in the treatment of certain disease states arising from pathologically overactivated glutamate receptors. Recently, we reported that certain urea-based structures act as potent inhibitors of GCPII (J. Med. Chem. 2001, 44, 298). However, many of the potent GCPII inhibitors prepared to date are highly polar compounds and therefore do not readily penetrate the blood-brain barrier. Herein, we elaborate on the synthesis of a series of potent, urea-based GCPII inhibitors from the lead compound 3 and provide assay data for these ligands against human GCPII. Moreover, we provide data revealing the ability of one of these compounds, namely, 8d, to reduce the perception of inflammatory pain. Within the present series, the γ-tetrazole bearing glutamate isostere 7d is the most potent inhibitor with a Ki of 0.9 nM. The biological evaluation of these compounds revealed that the active site of GCPII likely comprises two regions, namely, the pharmacophore subpocket and the nonpharmacophore subpocket. The pharmacophore subpocket is very sensitive to structural changes, and thus, it appears important to keep one of the glutamic acid moieties intact to maintain the potency of the GCPII inhibitors. The site encompassing the nonpharmacophore subpocket that binds to glutamate's α-carboxyl group is sensitive to structural change, as shown by compounds 6b and 7b. However, the other region of the nonpharmacophore subpocket can accommodate both hydrophobic and hydrophilic groups. Thus, an aromatic ring can be introduced to the inhibitor, as in 8b and 8d, thereby increasing its hydrophobicity and thus potentially its ability to cross the blood-brain barrier. Intrathecally administered 8d significantly reduced pain perception in the formalin model of rat sensory nerve injury. A maximal dose of morphine (10 mg) applied in the same experimental paradigm provided no significant increase in analgesia in comparison to 8d during phase 1 of this pain study and modestly greater analgesia than 8d in phase 2. These urea-based inhibitors of GCPII thus offer a novel approach to pain management.",
author = "Kozikowski, {Alan P.} and Jiazhong Zhang and Fajun Nan and Petukhov, {Pavel A.} and Ewa Grajkowska and Wroblewski, {Jarda T.} and Tatsuo Yamamoto and Tomasz Bzdega and Barbara Wroblewska and Neale, {Joseph H.}",
year = "2004",
month = "3",
day = "25",
doi = "10.1021/jm0306226",
language = "English (US)",
volume = "47",
pages = "1729--1738",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II

T2 - Efficacy as Analgesic Agents

AU - Kozikowski, Alan P.

AU - Zhang, Jiazhong

AU - Nan, Fajun

AU - Petukhov, Pavel A.

AU - Grajkowska, Ewa

AU - Wroblewski, Jarda T.

AU - Yamamoto, Tatsuo

AU - Bzdega, Tomasz

AU - Wroblewska, Barbara

AU - Neale, Joseph H.

PY - 2004/3/25

Y1 - 2004/3/25

N2 - The neuropeptidase glutamate carboxypeptidase II (GCPII) hydrolyzes N-acetyl-L-aspartyl-L-glutamate (NAAG) to liberate N-acetylaspartate and glutamate. GCPII was originally cloned as PSMA, an Mr 100 000 type II transmembrane glycoprotein highly expressed in prostate tissues. PSMA/GCPII is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. Inhibition of brain GCPII may have therapeutic potential in the treatment of certain disease states arising from pathologically overactivated glutamate receptors. Recently, we reported that certain urea-based structures act as potent inhibitors of GCPII (J. Med. Chem. 2001, 44, 298). However, many of the potent GCPII inhibitors prepared to date are highly polar compounds and therefore do not readily penetrate the blood-brain barrier. Herein, we elaborate on the synthesis of a series of potent, urea-based GCPII inhibitors from the lead compound 3 and provide assay data for these ligands against human GCPII. Moreover, we provide data revealing the ability of one of these compounds, namely, 8d, to reduce the perception of inflammatory pain. Within the present series, the γ-tetrazole bearing glutamate isostere 7d is the most potent inhibitor with a Ki of 0.9 nM. The biological evaluation of these compounds revealed that the active site of GCPII likely comprises two regions, namely, the pharmacophore subpocket and the nonpharmacophore subpocket. The pharmacophore subpocket is very sensitive to structural changes, and thus, it appears important to keep one of the glutamic acid moieties intact to maintain the potency of the GCPII inhibitors. The site encompassing the nonpharmacophore subpocket that binds to glutamate's α-carboxyl group is sensitive to structural change, as shown by compounds 6b and 7b. However, the other region of the nonpharmacophore subpocket can accommodate both hydrophobic and hydrophilic groups. Thus, an aromatic ring can be introduced to the inhibitor, as in 8b and 8d, thereby increasing its hydrophobicity and thus potentially its ability to cross the blood-brain barrier. Intrathecally administered 8d significantly reduced pain perception in the formalin model of rat sensory nerve injury. A maximal dose of morphine (10 mg) applied in the same experimental paradigm provided no significant increase in analgesia in comparison to 8d during phase 1 of this pain study and modestly greater analgesia than 8d in phase 2. These urea-based inhibitors of GCPII thus offer a novel approach to pain management.

AB - The neuropeptidase glutamate carboxypeptidase II (GCPII) hydrolyzes N-acetyl-L-aspartyl-L-glutamate (NAAG) to liberate N-acetylaspartate and glutamate. GCPII was originally cloned as PSMA, an Mr 100 000 type II transmembrane glycoprotein highly expressed in prostate tissues. PSMA/GCPII is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. Inhibition of brain GCPII may have therapeutic potential in the treatment of certain disease states arising from pathologically overactivated glutamate receptors. Recently, we reported that certain urea-based structures act as potent inhibitors of GCPII (J. Med. Chem. 2001, 44, 298). However, many of the potent GCPII inhibitors prepared to date are highly polar compounds and therefore do not readily penetrate the blood-brain barrier. Herein, we elaborate on the synthesis of a series of potent, urea-based GCPII inhibitors from the lead compound 3 and provide assay data for these ligands against human GCPII. Moreover, we provide data revealing the ability of one of these compounds, namely, 8d, to reduce the perception of inflammatory pain. Within the present series, the γ-tetrazole bearing glutamate isostere 7d is the most potent inhibitor with a Ki of 0.9 nM. The biological evaluation of these compounds revealed that the active site of GCPII likely comprises two regions, namely, the pharmacophore subpocket and the nonpharmacophore subpocket. The pharmacophore subpocket is very sensitive to structural changes, and thus, it appears important to keep one of the glutamic acid moieties intact to maintain the potency of the GCPII inhibitors. The site encompassing the nonpharmacophore subpocket that binds to glutamate's α-carboxyl group is sensitive to structural change, as shown by compounds 6b and 7b. However, the other region of the nonpharmacophore subpocket can accommodate both hydrophobic and hydrophilic groups. Thus, an aromatic ring can be introduced to the inhibitor, as in 8b and 8d, thereby increasing its hydrophobicity and thus potentially its ability to cross the blood-brain barrier. Intrathecally administered 8d significantly reduced pain perception in the formalin model of rat sensory nerve injury. A maximal dose of morphine (10 mg) applied in the same experimental paradigm provided no significant increase in analgesia in comparison to 8d during phase 1 of this pain study and modestly greater analgesia than 8d in phase 2. These urea-based inhibitors of GCPII thus offer a novel approach to pain management.

UR - http://www.scopus.com/inward/record.url?scp=12144289420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144289420&partnerID=8YFLogxK

U2 - 10.1021/jm0306226

DO - 10.1021/jm0306226

M3 - Article

C2 - 15027864

AN - SCOPUS:12144289420

VL - 47

SP - 1729

EP - 1738

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -